Franklin Resources Inc. boosted its stake in shares of Janux Therapeutics, Inc. ( NASDAQ:JANX – Free Report ) by 64.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,983 shares of the company’s stock after purchasing an additional 7,442 shares during the period. Franklin Resources Inc.’s holdings in Janux Therapeutics were worth $937,000 at the end of the most recent reporting period. A number of other hedge funds also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its position in shares of Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after buying an additional 156,675 shares during the period. Ally Bridge Group NY LLC purchased a new position in shares of Janux Therapeutics in the 3rd quarter worth about $4,943,000. Algert Global LLC acquired a new position in shares of Janux Therapeutics in the 3rd quarter valued at about $1,112,000. FMR LLC grew its holdings in shares of Janux Therapeutics by 0.6% during the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after purchasing an additional 47,075 shares during the period. Finally, Neo Ivy Capital Management acquired a new stake in Janux Therapeutics during the 3rd quarter worth approximately $940,000. Institutional investors and hedge funds own 75.39% of the company’s stock. Analyst Upgrades and Downgrades Several equities research analysts have issued reports on JANX shares. Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. HC Wainwright raised their price objective on Janux Therapeutics from $63.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday. Scotiabank increased their target price on Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a research note on Wednesday, December 4th. Finally, BTIG Research boosted their price target on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Janux Therapeutics presently has a consensus rating of “Buy” and an average target price of $89.90. Insider Buying and Selling at Janux Therapeutics In other Janux Therapeutics news, Director Ra Capital Management, L.P. acquired 1,200,000 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was acquired at an average price of $44.75 per share, with a total value of $53,700,000.00. Following the transaction, the director now directly owns 9,317,246 shares in the company, valued at approximately $416,946,758.50. This represents a 14.78 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link . Also, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $46.24, for a total transaction of $44,297.92. Following the sale, the insider now owns 6,887 shares in the company, valued at approximately $318,454.88. This trade represents a 12.21 % decrease in their position. The disclosure for this sale can be found here . Insiders have sold 92,801 shares of company stock worth $5,174,735 over the last quarter. 29.40% of the stock is owned by corporate insiders. Janux Therapeutics Trading Down 1.9 % Shares of NASDAQ:JANX opened at $54.10 on Friday. Janux Therapeutics, Inc. has a 12-month low of $7.79 and a 12-month high of $71.71. The firm has a market cap of $2.84 billion, a PE ratio of -46.24 and a beta of 3.29. The company has a fifty day simple moving average of $54.43 and a 200 day simple moving average of $47.46. Janux Therapeutics ( NASDAQ:JANX – Get Free Report ) last issued its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The company had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business’s revenue was down 82.6% on a year-over-year basis. As a group, equities research analysts forecast that Janux Therapeutics, Inc. will post -1.35 EPS for the current fiscal year. About Janux Therapeutics ( Free Report ) Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Read More Five stocks we like better than Janux Therapeutics Using the MarketBeat Dividend Tax Calculator Buffett Takes the Bait; Berkshire Buys More Oxy in December Should You Add These Warren Buffett Stocks to Your Portfolio? Top 3 ETFs to Hedge Against Inflation in 2025 What Are Trending Stocks? Trending Stocks Explained These 3 Chip Stock Kings Are Still Buys for 2025 Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .Vertiv Holdings Co ( NYSE:VRT – Get Free Report ) shares were down 3.5% during mid-day trading on Friday . The company traded as low as $113.70 and last traded at $114.67. Approximately 1,433,155 shares were traded during trading, a decline of 82% from the average daily volume of 8,007,207 shares. The stock had previously closed at $118.88. Wall Street Analyst Weigh In VRT has been the topic of a number of recent research reports. The Goldman Sachs Group lifted their target price on shares of Vertiv from $126.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, November 19th. Bank of America upped their target price on shares of Vertiv from $130.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, October 24th. Oppenheimer raised their price target on Vertiv from $121.00 to $131.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. Evercore ISI upped their price objective on Vertiv from $125.00 to $135.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Finally, UBS Group began coverage on Vertiv in a research note on Wednesday, November 13th. They issued a “buy” rating and a $155.00 target price on the stock. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Vertiv presently has an average rating of “Moderate Buy” and an average price target of $140.09. View Our Latest Stock Report on VRT Vertiv Stock Down 3.2 % Vertiv ( NYSE:VRT – Get Free Report ) last released its quarterly earnings data on Wednesday, October 23rd. The company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.07. Vertiv had a net margin of 7.72% and a return on equity of 55.33%. The firm had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $1.98 billion. During the same quarter in the previous year, the firm earned $0.52 earnings per share. The firm’s revenue was up 19.0% on a year-over-year basis. As a group, equities research analysts forecast that Vertiv Holdings Co will post 2.69 earnings per share for the current year. Vertiv Increases Dividend The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 19th. Investors of record on Tuesday, December 3rd were issued a dividend of $0.0375 per share. The ex-dividend date of this dividend was Tuesday, December 3rd. This is a boost from Vertiv’s previous quarterly dividend of $0.03. This represents a $0.15 annualized dividend and a yield of 0.13%. Vertiv’s payout ratio is currently 6.67%. Insider Buying and Selling at Vertiv In related news, EVP Stephen Liang sold 86,619 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $131.07, for a total value of $11,353,152.33. Following the sale, the executive vice president now directly owns 19,551 shares in the company, valued at $2,562,549.57. The trade was a 81.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink . Also, Director Jakki L. Haussler sold 15,347 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $137.38, for a total transaction of $2,108,370.86. Following the transaction, the director now owns 3,425 shares of the company’s stock, valued at $470,526.50. This trade represents a 81.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Over the last 90 days, insiders have sold 171,527 shares of company stock valued at $23,105,682. Insiders own 5.01% of the company’s stock. Institutional Investors Weigh In On Vertiv Large investors have recently bought and sold shares of the stock. Jennison Associates LLC raised its holdings in shares of Vertiv by 10,825.0% in the third quarter. Jennison Associates LLC now owns 4,600,415 shares of the company’s stock worth $457,695,000 after acquiring an additional 4,558,306 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in Vertiv during the 2nd quarter worth about $331,091,000. Wellington Management Group LLP raised its stake in Vertiv by 271.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,915,446 shares of the company’s stock valued at $389,548,000 after purchasing an additional 2,860,181 shares during the last quarter. Castle Hook Partners LP lifted its holdings in Vertiv by 215.6% in the 3rd quarter. Castle Hook Partners LP now owns 1,864,426 shares of the company’s stock valued at $185,492,000 after purchasing an additional 1,273,746 shares in the last quarter. Finally, Whale Rock Capital Management LLC acquired a new stake in shares of Vertiv during the 3rd quarter worth about $110,517,000. Institutional investors and hedge funds own 89.92% of the company’s stock. About Vertiv ( Get Free Report ) Vertiv Holdings Co, together with its subsidiaries, designs, manufactures, and services critical digital infrastructure technologies and life cycle services for data centers, communication networks, and commercial and industrial environments in the Americas, the Asia Pacific, Europe, the Middle East, and Africa. Recommended Stories Receive News & Ratings for Vertiv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertiv and related companies with MarketBeat.com's FREE daily email newsletter .
RAY MASSEY: It's time to consult my trusty crystal ball for 2025's motoring predictions
Taiwan’S Smart Technology And Innovative Economy Core To National Development Plan And Development StrategiesFirefighters and passengers hurt after train hits fire truck on crossing
Santosh Trophy: Kerala register emphatic 5-1 win over Manipur, will face West Bengal in final